Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) An ~~novel α2~~ crystalline form of Imatinib Mesylate which has ~~is stable at room temperature and even at higher temperatures like 120°C and accelerated stress conditions, freely soluble in water and having~~ the XRPD characteristics given below

~~Table I~~

Angle 2-Theta	d Value Angstrom	Intensity %
4.841	18.24057	33.6
10.410	8.49070	100.0
11.194	7.89775	14.2
11.856	7.45827	19.9
12.881	6.86709	6.8
13.819	6.40328	12.9
14.860	5.95663	67.7
16.439	5.38788	32.4
17.049	5.19665	5.6
17.623	5.02870	58.6
18.052	4.91000	61.6
18.567	4.77491	98.8
19.032	4.65925	70.2
19.772	4.48657	15.3
21.236	4.18055	60.8
21.582	4.11431	59.4
22.594	3.93217	19.7
23.137	3.84112	21.8
23.696	3.75172	25.0
24.851	3.57993	58.6
26.250	3.39226	9.1
27.341	3.25932	18.7
28.475	3.13204	42.4
31.896	2.80347	9.0
32.533	2.75005	6.6
43.447	2.08117	6.4

which is sufficiently stable that it retains these XRPD characteristics after 6 hours at 120 °C and/or after 6 months at about 40 °C and about 75% relative humidity; and which is a solid in the form of free flowing crystals that are not needle shaped.

2. (Currently amended) A process for the preparation of an ~~novel~~ α_2 crystalline form of Imatinib Mesylate, the process comprising: ~~comprises~~

suspending Imatinib base in isopropanol; ~~and~~

adding methane sulfonic acid at room temperature; ~~and~~

maintaining the reaction mixture at a temperature ~~in the range~~ of 40-80°C for ~~a period in the range of~~ 20-30 minutes, and

cooling to 40-45 °C and filtering to obtain the α_2 crystal form;

wherein the α_2 crystal form has the XRPD characteristics given below,

Angle 2-Theta	d Value Angstrom	Intensity %
4.841	18.24057	33.6
10.410	8.49070	100.0
11.194	7.89775	14.2
11.856	7.45827	19.9
12.881	6.86709	6.8
13.819	6.40328	12.9
14.860	5.95663	67.7
16.439	5.38788	32.4
17.049	5.19665	5.6
17.623	5.02870	58.6
18.052	4.91000	61.6
18.567	4.77491	98.8
19.032	4.65925	70.2
19.772	4.48657	15.3
21.236	4.18055	60.8
21.582	4.11431	59.4
22.594	3.93217	19.7
23.137	3.84112	21.8
23.696	3.75172	25.0
24.851	3.57993	58.6
26.250	3.39226	9.1
27.341	3.25932	18.7

28.475	3.13204	42.4
31.896	2.80347	9.0
32.533	2.75005	6.6
43.447	2.08117	6.4

is sufficiently stable that it retains these XRPD characteristics after 6 hours at 120 °C and/or after 6 months at about 40 °C and about 75% relative humidity; and is a solid in the form of free flowing crystals that are not needle shaped.

3. (Currently amended) A process for the preparation of an ~~novel, stable~~ α_2 crystalline form of Imatinib Mesylate, the process comprising: ~~which comprises~~

suspending β polymorphic form Imatinib Mesylate in water and an organic solvent, ~~s like~~ the organic solvent comprising methanol, Isopropyl ether, toluene, cyclohexane, or ~~and~~ Isopropyl alcohol;[[,]]

distilling off water azeotropically; and[[,]]

cooling and filtering to obtain the α_2 crystal form;

wherein the α_2 crystal form has the XRPD characteristics given below,

Angle 2-Theta	d Value Angstrom	Intensity %
4.841	18.24057	33.6
10.410	8.49070	100.0
11.194	7.89775	14.2
11.856	7.45827	19.9
12.881	6.86709	6.8
13.819	6.40328	12.9
14.860	5.95663	67.7
16.439	5.38788	32.4
17.049	5.19665	5.6
17.623	5.02870	58.6
18.052	4.91000	61.6
18.567	4.77491	98.8
19.032	4.65925	70.2
19.772	4.48657	15.3
21.236	4.18055	60.8
21.582	4.11431	59.4
22.594	3.93217	19.7

23.137	3.84112	21.8
23.696	3.75172	25.0
24.851	3.57993	58.6
26.250	3.39226	9.1
27.341	3.25932	18.7
28.475	3.13204	42.4
31.896	2.80347	9.0
32.533	2.75005	6.6
43.447	2.08117	6.4

is sufficiently stable that it retains these XRPD characteristics after 6 hours at 120 °C and/or after 6 months at about 40 °C and about 75% relative humidity; and is a solid in the form of free flowing crystals that are not needle shaped.

4. (Currently amended) A pharmaceutical composition comprising: ~~containing novel α_2 crystalline form of Imatinib Mesylate which is stable at room temperature and even at higher temperatures like and accelerated stress conditions, freely soluble in water and having the characteristics given in the Table 1 shown in claim1 along with the usual exepients useful for the treatment of chronic myelogenous leukemia~~

an excipient; and

an α_2 crystal form of Imatinib mesylate that has the XRPD characteristics given below,

Angle 2-Theta	d Value Angstrom	Intensity %
4.841	18.24057	33.6
10.410	8.49070	100.0
11.194	7.89775	14.2
11.856	7.45827	19.9
12.881	6.86709	6.8
13.819	6.40328	12.9
14.860	5.95663	67.7
16.439	5.38788	32.4
17.049	5.19665	5.6
17.623	5.02870	58.6
18.052	4.91000	61.6
18.567	4.77491	98.8
19.032	4.65925	70.2
19.772	4.48657	15.3

21.236	4.18055	60.8
21.582	4.11431	59.4
22.594	3.93217	19.7
23.137	3.84112	21.8
23.696	3.75172	25.0
24.851	3.57993	58.6
26.250	3.39226	9.1
27.341	3.25932	18.7
28.475	3.13204	42.4
31.896	2.80347	9.0
32.533	2.75005	6.6
43.447	2.08117	6.4

is sufficiently stable that it retains these XRPD characteristics after 6 hours at 120 °C and/or after 6 months at about 40 °C and about 75% relative humidity; and is a solid in the form of free flowing crystals that are not needle shaped.

5. (Currently amended) [[A]] The pharmaceutical composition of ~~as claimed in~~ claim 4, comprising ~~wherein the active ingredient used ranges from~~ 45[[%]] to 60 wt-% the α_2 crystal form of Imatinib mesylate.

6. (Currently amended) [[A]] The pharmaceutical composition of ~~as claimed in~~ claim 4, wherein the excipients ~~used is selected from~~ comprises microcrystalline cellulose, XL, colloidal silicone dioxide, magnesium stearate, ~~and~~ talc, or a ~~their~~ mixture[[s]] thereof.

7. (Currently amended) ~~An improved~~ process for the preparation of an α_2 crystal form of Imatinib mesylate the process comprising: ~~polymorphic form which comprises~~

suspending Imatinib base in a solvent, the solvent comprising ~~selected from~~ acetone, acetonitrile, a mixture of methanol and isopropanol, or a ~~and~~ mixture of isopropanol and water; ~~and~~

adding methane sulfonic acid to the resulting suspension ~~solution~~ at room temperature; ~~and~~

maintaining the solution at the reflux temperature of the solvent [[()]or[[]]] at room temperature; and

filtering to obtain the α_2 crystal form;

wherein the α_2 crystal form has the XRPD characteristics given below,

Angle 2-Theta	d Value Angstrom	Intensity %
4.841	18.24057	33.6
10.410	8.49070	100.0
11.194	7.89775	14.2
11.856	7.45827	19.9
12.881	6.86709	6.8
13.819	6.40328	12.9
14.860	5.95663	67.7
16.439	5.38788	32.4
17.049	5.19665	5.6
17.623	5.02870	58.6
18.052	4.91000	61.6
18.567	4.77491	98.8
19.032	4.65925	70.2
19.772	4.48657	15.3
21.236	4.18055	60.8
21.582	4.11431	59.4
22.594	3.93217	19.7
23.137	3.84112	21.8
23.696	3.75172	25.0
24.851	3.57993	58.6
26.250	3.39226	9.1
27.341	3.25932	18.7
28.475	3.13204	42.4
31.896	2.80347	9.0
32.533	2.75005	6.6
43.447	2.08117	6.4

is sufficiently stable that it retains these XRPD characteristics after 6 hours at 120 °C and/or after 6 months at about 40 °C and about 75% relative humidity; and is a solid in the form of free flowing crystals that are not needle shaped.